BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

CKGSB and Johns Hopkins Launch AI-Driven Healthcare Innovation Program for Senior Leaders

The Cheung Kong Graduate School of Business (CKGSB) and Johns Hopkins University's Carey Business School are proud to announce the launch of...

February 20, 2025 | News

CanSinoBIO Showcases Vaccine Innovation and Global Health Commitment at 2025 World Government Summit

CanSino Biologics Inc. (CanSinoBIO or the Company), a leading Chinese vaccine innovator, has been invited to the 2025 World Government Summit in Dubai...

February 18, 2025 | News

Fosun Pharma Accelerates AI-Driven Transformation in Healthcare and Drug Development

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovati...

February 18, 2025 | News

Kexing Biopharm Receives FDA Approval for Clinical Trials of GB05 Inhalation Therapy for Pediatric RSV Infections

Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1...

February 17, 2025 | News

Innovent’s IBI363 Secures Second FDA Fast Track Designation for Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

February 17, 2025 | News

Akeso Receives IND Approval in China for AK139, the First IL-4Rα/ST2 Bispecific Antibody

Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (...

February 14, 2025 | News

Alphamab Oncology Doses First Patient in Phase III Study of Anti-HER2 ADC JSKN003 for Platinum-Resistant Ovarian Cancer

Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...

February 14, 2025 | News

Akeso Initiates Phase 3 Trial in China for Cadonilimab as Consolidation Therapy in Advanced NSCLC

Akeso, Inc. announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION...

February 13, 2025 | News

AIM Vaccine Leads China's mRNA Innovation, Submits Breakthrough Shingles Vaccine for Clinical Trials

AIM Vaccine Co, a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA s...

February 12, 2025 | News

China's BioRay Secures NMPA Nod for Clinical Trials of BR111, a First-in-Class Anti-ROR1 ADC

BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application f...

February 11, 2025 | News

Keymed Biosciences Gains NMPA Approval for Stapokibart in Treating Seasonal Allergic Rhinitis

Keymed Biosciences announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug A...

February 10, 2025 | News

Nuance Pharma Secures First Regulatory Approval for Ohtuvayre™ in Macau for COPD Treatment

Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance tr...

February 07, 2025 | News

Alphamab Oncology and CSPC Launch Phase III Trial for Anti-HER2 ADC JSKN003 in Advanced Breast Cancer

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has rece...

February 07, 2025 | News

Henlius and Dr. Reddy’s Forge Licensing Deal for Daratumumab Biosimilar in U.S. and Europe

Shanghai Henlius Biotech, Inc. announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Redd...

February 07, 2025 | News

Stay Connected